Frédéric Pouliot
YOU?
Author Swipe
View article: LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21
LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21 Open
View article: Ex vivo culture to evaluate dynamic changes in the tumor microenvironment following durvalumab treatment
Ex vivo culture to evaluate dynamic changes in the tumor microenvironment following durvalumab treatment Open
While the tumor microenvironment (TME) is critical to the mechanism of action of anti-PD-1/PD-L1 checkpoint inhibitions, limitations exist to understand this using in vitro and in vivo models. With bladder (BCa) and prostate (PCa) cancer r…
View article: Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma Open
Background Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC (nccRCC), representing up to 15% of RCC cases. Phase 2 trials have evaluated first-line (1L) immunotherapy (IO)-based treatment in nccRCC, but with hete…
View article: Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial Open
View article: 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update)
2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update) Open
View article: The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study Open
View article: 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update)
2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update) Open
View article: Sexual activity in men undergoing ADT for localized prostate cancer: a narrative literature review
Sexual activity in men undergoing ADT for localized prostate cancer: a narrative literature review Open
Androgen deprivation therapy (ADT) can negatively affect sexual function, and only a minority of patients report sexual activity. We reviewed the existing literature regarding the proportion of men who remained sexually active during and a…
View article: Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer
Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer Open
Prostate cancer is a leading malignancy affecting men globally and in Canada. Biochemical recurrence (BCR), marked by rising prostate-specific antigen (PSA) levels post-curative intended local treatment, is prevalent in nearly one-third of…
View article: Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients Open
Background: Ipilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium (IMDC) …
View article: Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma? Open
Objective To evaluate and compare the outcomes of patients with localised renal cell carcinoma (RCC) with and without sarcomatoid features and the impact of this on cancer recurrence and survival. Material and Methods The Canadian Kidney C…
View article: Multi-task Bayesian model combining FDG-PET/CT imaging and clinical data for interpretable high-grade prostate cancer prognosis
Multi-task Bayesian model combining FDG-PET/CT imaging and clinical data for interpretable high-grade prostate cancer prognosis Open
We propose a fully automatic multi-task Bayesian model, named Bayesian Sequential Network (BSN), for predicting high-grade (Gleason $$\ge$$ 8) prostate cancer (PCa) prognosis using pre-prostatectomy FDG-PET/CT images and clinical data. B…
View article: Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study Open
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was de…
View article: Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database
Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database Open
Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but i…
View article: PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlight
PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlight Open
The prevailing biomarker employed for prostate cancer (PCa) screening and diagnosis is the prostate-specific antigen (PSA). Despite excellent sensitivity, PSA lacks specificity, leading to false positives, unnecessary biopsies and overdiag…
View article: Protocol for transducing human primary epithelial prostate cells and patient-derived organoids with high efficiency
Protocol for transducing human primary epithelial prostate cells and patient-derived organoids with high efficiency Open
View article: Multi-task Bayesian Model Combining FDG-PET/CT Imaging and Clinical Data for Interpretable High-Grade Prostate Cancer Prognosis
Multi-task Bayesian Model Combining FDG-PET/CT Imaging and Clinical Data for Interpretable High-Grade Prostate Cancer Prognosis Open
We propose a fully automatic multi-task Bayesian model, named Bayesian Sequential Network (BSN), for predicting high-grade (Gleason ≥ 8) prostate cancer (PCa) prognosis using pre-prostatectomy FDG-PET/CT images and clinical data. BSN perfo…
View article: The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression Open
Just like the androgen receptor (AR), the estrogen receptor α (ERα) is expressed in the prostate and is thought to influence prostate cancer (PCa) biology. Yet the incomplete understanding of ERα functions in PCa hinders our ability to ful…
View article: An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells
An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells Open
Prostate cancer (PCa) displays diverse intra-tumoral traits, impacting its progression and treatment outcomes. This study aimed to refine PCa cell culture conditions for dynamic monitoring of androgen receptor (AR) activity at the single-c…
View article: Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy
Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy Open
Nguyen et al Metabolic, cardiac, and bone health in PCa patients on
View article: 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice Open
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castrati…
View article: Addressing controversial areas in the management of advanced prostate cancer in Canada
Addressing controversial areas in the management of advanced prostate cancer in Canada Open
Introduction: The management of prostate cancer (PCa) is rapidly evolving. Treatment and diagnostic options grow annually, however, high-level evidence for the use of new therapeutics and diagnostics is lacking. In November 2022, the Genit…
View article: The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors at Canadian academic centers
The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors at Canadian academic centers Open
Introduction: Robotic surgery is used in the treatment of kidney tumors. We aimed to determine if robotic access was associated with initial choice of management for patients with a clinical stage I kidney mass. Methods: Patients with a cl…
View article: Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC
Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC Open
Introduction: Bacillus Calmette-Guérin (BCG) failure occurs in approximately 40% of patients with non-muscle-invasive bladder cancer (NMIBC) within two years. We describe our institutional experience with sequential intravesical gemcitabin…
View article: Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial
Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial Open
Background In the general population, a higher omega‐3 polyunsaturated fatty acids intake is associated with lower levels of several psychological symptoms, especially depression. However, the existing evidence in cancer is equivocal. Meth…
View article: Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System
Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System Open
PURPOSE Standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have greatly evolved. However, the availability of emerging options in global health care systems can vary. We sought to describe the integration and usage of sy…
View article: Genetic testing practices among specialist physicians who treat prostate cancer
Genetic testing practices among specialist physicians who treat prostate cancer Open
Introduction: In patients with prostate cancer (PCa), the identification of an alteration in genes associated with homologous recombination repair (HRR) has implications for prognostication, optimization of therapy, and familial risk mitig…
View article: Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial
Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial Open
Background The impact of molecular imaging (MI) on patient management after biochemical recurrence (BCR) following radical prostatectomy has been described in many studies. However, it is not known if MI-induced management changes are appr…
View article: 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions
2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions Open
The current guideline summarizes the state-of-the-art knowledge on the management of cystic renal lesions by updating the 2017 Canadian Urological Association (CUA) guideline on the topic.To do so, we updated our search strategy on June 18…
View article: Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer Open
The androgen receptor (AR) is an established orchestrator of cell metabolism in prostate cancer (PCa), notably by inducing an oxidative mitochondrial program. Intriguingly, AR regulates cytoplasmic isocitrate dehydrogenase 1 (IDH1), but no…